Health and Fitness Health and Fitness
Thu, January 3, 2013
Wed, January 2, 2013
[ Wed, Jan 02nd 2013 ] - Market Wire
BE Resources Corporate Update

Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference


Published on 2013-01-02 14:00:50 - Market Wire
  Print publication without navigation


Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference -- DUBLIN, Jan. 2, 2013 /PRNewswire/ --

DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: [ JAZZ ]) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT).  Bruce Cozadd , chairman and chief executive officer of Jazz Pharmaceuticals, will present an overview of the company and provide a business and financial update.

The webcast can be accessed from the Investors section of the Jazz Pharmaceuticals website at [ www.jazzpharmaceuticals.com ].  An archived version of the webcast will be available at the same location for at least one week following the presentation.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma. For further information, see [ www.jazzpharmaceuticals.com ].

SOURCE Jazz Pharmaceuticals plc



RELATED LINKS
[ http://www.jazzpharma.com ]